To answer the question if also a selective FLT3 inhibitor could enhance GvL-effect, Zhang and colleagues studied IL-15 production and T cell activation in a mouse model of FLT3-ITD-positive AML relapse after allo-HCT treated with gilteritinib with or without T lymphocyte infusion [21]. The gene discussed is FLT3; the disease is acute myeloid leukemia.